183438-24-6

Basic information

• Product Name: 5-Bromo-2-iodopyrimidine
• Synonyms: 5-BROMO-2-IODOPYRIMIDINE;5-Bromo-iodopyrimidine;5-Brmo-2-iodopyrimidine;5-bromo-2-iodopyrimine;2-broMo-5-iodopyriMidine;5-BroMo-2-iodopyriMidine (This product is unavailable in the U.S.);5-Bromo-2-iodo-1,3-diazine;5-BroMo-2-iodopyriMidine
• CAS NO: 183438-24-6
• Molecular Formula: C₄H₂BrIN₂
• Molecular Weight: 284.88
• EINECS: 1312995-182-4
• Product Categories: Pyrimidine Series;Halides;Heterocycles;Pyridines, Pyrimidines, Purines and Pteredines;Pyrazines, Pyrimidines & Pyridazines;Pyrimidine;Pyrazines, Pyrimidines & Pyridazines;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrimidines;PyrimidinesHeterocyclic Building Blocks;Heterocycle-Pyrimidine series
• Mol File: 183438-24-6.mol

Chemical Properties

• Melting Point: 99-103 °C(lit.)
• Boiling Point: 341 °C at 760 mmHg
• Flash Point: 160 °C
• Appearance: White to tan/Crystalline Powder
• Density: 2.495 g/cm³
• Vapor Pressure: 0.000164mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -2.56±0.22(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 5-Bromo-2-iodopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-iodopyrimidine(183438-24-6)
• EPA Substance Registry System: 5-Bromo-2-iodopyrimidine(183438-24-6)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36/38-36/37/38
• Safety Statements: 26-37/39-37
• WGK Germany: 3
• HazardClass: IRRITANT, LIGHT SENSITIVE
• Hazardous Substances Data: 183438-24-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-iodopyrimidine is used as a key intermediate in the synthesis of various organic compounds, such as 5,5′-dibromo-2,2′-bipyrimidine and O,O′-dimethyl hyrtinadine A. Its unique structure and reactivity make it a valuable building block for the development of new pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-2-iodopyrimidine is used as a starting material for the synthesis of novel therapeutic agents. Its halogenated pyrimidine structure can be further modified and functionalized to create new drug candidates with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Agrochemical Industry:
5-Bromo-2-iodopyrimidine can also be utilized in the agrochemical industry for the development of new pesticides and herbicides. Its chemical properties and reactivity allow for the creation of new active ingredients with improved efficacy, selectivity, and environmental compatibility.
Used in Research and Development:
In the field of research and development, 5-Bromo-2-iodopyrimidine serves as a valuable tool for studying the structure-activity relationships of pyrimidine-based compounds. It can be used to investigate the effects of halogenation on the biological activity and physicochemical properties of pyrimidines, providing insights into the design of new and improved pyrimidine-containing molecules.

InChI:InChI=1/C4H2BrIN2/c5-3-1-7-4(6)8-2-3/h1-2H

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 38353-09-2 2-hydroxypyrimidine hydrochloride 
• 7752-82-1 5-bromo-2-aminopyrimidine 
• 38353-09-2 2-pyrimidinone hydrochloride 

Downstream Products

• 183437-94-7 5-bromo-2-(4-fluorophenyl)pyrimidine 
• 183437-80-1 5-bromo-2-(4-(trifluoromethyl)phenyl)pyrimidine 
• 183437-82-3 2-(3',4'-Difluorophenyl)-5-bromopyrimidine 
• 167018-88-4 2-(2',3'-difluoro-4'-octyloxyphenyl)-5-bromopyrimidine 
• 223609-50-5 5-bromo-2-(phenylethynyl)pyrimidine 
• 328233-73-4 C₃₄H₄₀Br₂N₄ 
• 328233-76-7 C₅₀H₆₁BrN₄ 
• 372954-59-1 5-bromo-2-(4-trimethylsilanylethynyl-phenyl)-pyrimidine 
• 442899-45-8 2,5-bis(4-octyloxyphenyl)pyrimidine 
• 7752-78-5 5-bromo-2-methylpyrimidine 
• 177727-12-7 C₁₁H₉BrN₂O 
• 890021-36-0 5-bromo-2-(3-fluoro-4-methoxyphenyl)pyrimidine 
• 927805-70-7 2-(5-bromopyrimidin-2-yl)-3-(tert-butyldiphenylsilyloxy)furo[2,3-c]pyridine 
• 883901-68-6 5-bromo-2-vinyl-pyrimidine 

Relevant articles and documents

The synthesis and characterisation of novel thienyl-pyrimidine liquid crystalline materials

The synthesis and transition temperatures of a series of novel thienyl-pyrimidine liquid crystalline materials is described. Palladium catalysed coupling of 5-n-alkyl-2-tri-n-butylstannyl thiophenes to 5-bromo-2-iodopyrimidine is used to create novel pyrimidine compounds which exhibit lower melting points than similar pyrimidine liquid crystals. These compounds exhibit a variety of phases including smectic A, C, G, B and hexstatic B also they exhibit several as yet unidentifiable phases. Speculation as to hydrogen bonding in the liquid crystalline core is also discussed therein.

Systematic studies using 2-(1-adamantylethynyl)pyrimidine-5-carbaldehyde as a starting material in soai's asymmetric autocatalysis

Herein, we present a new substrate for the Soai reaction, which has an adamantylethynyl residue (1g) and exhibits asymmetric autocatalysis, yielding products with enantiomeric excesses above 99%. For the first time, all reactions were performed on a parallel synthesizer system to ensure identical reaction conditions. A detailed systematic study of reaction parameters was performed and we report the highest enhancements of enantiomeric excess reported so far in the Soai reaction in one reaction cycle (7.2→94.1% ee or 3.1→92.1% ee). Our results led to a set of reaction parameters that yield reproducible results. Therefore, our new starting material 1g is suitable for systematic and mechanistic studies on this remarkable reaction. A series of experiments designed to quantify the amplification of enantiomeric excess demonstrated that the reaction can be used in principle as a tool for the detection of low enantiomeric excesses: under definite conditions, an unknown low enantiomeric excess (0.1-7%) was amplified to a detectable one. A back calculation to the original value offers a new method for the determination of small enantiomeric excesses.

ORGANIC COMPOUNDS, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTID DEVICE HAVING THE COMPOUNDS

The present invention relates to an organic compound in which a bipyrimidine moiety serving as an electron acceptor is connected via an aromatic linker to a hetero-aromatic moiety serving as an electron donor and containing one to two nitrogen atoms. The organic compound, since it contains both electron donor and electron acceptor moieties in a single molecule, allows electric charges to move easily, thereby increasing luminance efficiency. Also, since the electron donor is made of solid condensed aromatic rings, such as carbazole, acridine, or indole rings, the 3D structure of the molecule is hindered. Thus, the organic compound of the present invention may be used as a delayed fluorescence dopant emitting a blue light of high chromatic purity. The organic compound of the present invention may be applied to organic light-emitting devices, such as an organic light-emitting diode, a display device, and a lighting device, to lower the driving voltage thereof while increasing luminance efficiency and chromatic purity thereof.COPYRIGHT KIPO 2019

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

TRICYCLIC GYRASE INHIBITORS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

Preparation of highly reactive pyridine- and pyrimidine-containing diarylamine antioxidants

We recently reported a preliminary account of our efforts to develop novel diarylamine radical-trapping antioxidants (Hanthorn, J. J. et al. J. Am. Chem. Soc. 2012, 134, 8306-8309) wherein we demonstrated that the incorporation of ring nitrogens into diphenylamines affords compounds which display a compromise between H-atom transfer reactivity to peroxyl radicals and stability to one-electron oxidation. Herein we provide the details of the synthetic efforts associated with that report, which have been substantially expanded to produce a library of substituted heterocyclic diarylamines that we have used to provide further insight into the structure-reactivity relationships of these compounds as antioxidants (see the accompanying paper, DOI: 10.1021/jo301012x). The diarylamines were prepared in short, modular sequences from 2-aminopyridine and 2-aminopyrimidine wherein aminations of intermediate pyri(mi)dyl bromides and then Pd-catalyzed cross-coupling reactions of the amines and precursor bromides were the key steps to yield the diarylamines. The cross-coupling reactions were found to proceed best with Pd(η3-1-PhC3H 4)(η5-C5H5) as precatalyst, which gave higher yields than the conventional Pd source, Pd2(dba) 3.

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Novel diazine derivatives

The present invention provides compounds of formula (I): their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.